Advertisement
CGTX 外匯新聞
Cognition Reports Positive Topline Results For CT1812 Phase 2 SEQUEL Study For Alzheimer's Disease
Neuroscience company Cognition Therapeutics, Inc. (CGTX) announced Wednesday topline results from its Phase 2 double-blind, single-crossover SEQUEL study (NCT04735536) of CT1812 in 16 adults with mild-to-moderate Alzheimer's disease.
RTTNews
|
688天前
